Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07734103
PHASE2

Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder

Sponsor: CSTrials Inc.

View on ClinicalTrials.gov

Summary

The primary objective of this study is to evaluate the efficacy and tolerability of Lumateperone in reducing stuttering symptoms. The following scales and samples will be collected for clinical and functional outcomes. • MLGSSS • SSS • Stuttering Severity Instrument (SSI-IV) • PHQ-9 • Barnes Akathisia • SAS • AIMS • CGI-I • CGI-S

Official title: A Single-Center, Double-Blind, Placebo-Controlled, Study to Evaluate Lumateperone, Flexible Doses of 21mg or 42mg in Patients With Moderate to Severe Childhood Onset Fluency Disorder, Stuttering.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2026-04-18

Completion Date

2027-10-31

Last Updated

2026-07-29

Healthy Volunteers

No

Interventions

DRUG

Lumateperone (ITI-007)

This medication is a tablet that is taken once daily

DRUG

Placebo Tablet or Capsule

Matching Placebo

Locations (1)

CSTrials

Costa Mesa, California, United States